The newly launched AtriClip Pro-V is designed to be placed through a minimally-invasive surgery and features an open-ended design and tip-first closure mechanism for easier navigation, the Mason, Ohio.-based company claims.
“Development of the AtriClip Pro-V is another step in the direction of a comprehensive strategy for management of the left atrial appendage. It expands the options for minimally invasive approaches including right chest access and an easier implantation of an epicardial atrial appendage clip. AtriCure has been consistently working for decades to improve patients’ lives by offering devices for atrial fibrillation ablation and left atrial appendage closure. Development of this new AtriClip device is another significant step in this direction, which improves access to the appendage and makes it easier to visualize and apply the AtriClip at the base of the appendage utilizing minimally invasive techniques. Our team at Pinnacle Health is privileged to be part of this development,” Dr. Mubashir A. Mumtaz of Pennsylvania’s Pinnacle Health said in a press release.
AtriCure said that the Pro-V has identical force and pressure specifications to other closed-end designed AtriClip devices, including the Flex and Pro2, and that the device is compatible with 12mm ports and can be repositioned multiple times before deployment.
“The AtriClip franchise continues to be the fastest growing part of our business, and we are excited to add another piece to our portfolio with the AtriClip Pro-V. The advancements with the open-ended design provides a more flexible approach in MIS therapies. Additionally, early experience and feedback from customers utilizing the device to treat patients has been excellent, and we are happy to now make the product available to all customers in the U.S. This platform will also serve as the foundation for future innovation and increasingly less invasive applications of our AtriClip platform,” CEO & prez Michael Carrel said in a prepared statement.
The AtriClip Pro-V won FDA 510(k) clearance in March 2016, but only saw a limited release, AtriCure said.
In July, AtriCure saw shares rise after it reported higher-than-expected sales and raised its outlook for the rest of the year.